Kent Kester, MD, is appointed as SAB Chair. The Geneva Foundation (Geneva) announces today the appointment of four new members to its Scientific Advisory Board (SAB) which provides scientific consult, advisement, and direction to Geneva’s senior leadership, program directors, principal investigators, and research administrators. “It is a great honor to take on the role
Category: Press Release
PREVIOUS GENEVA VICE CHAIR NEIL VINING, MD, MBA IS APPOINTED AS BOARD CHAIR. The Geneva Foundation (Geneva) announces changes to its Board of Directors with several new additions and the appointment of Dr. Neil Vining as Chair. The additions, and appointment of a new Chair, come as several long-serving members retired from the Board of Directors
LT. COL. (P) ECKERT AND CAPT. LAMMERS WILL PRESENT THEIR RESEARCH FINDINGS TO THE PUBLIC NEXT MONTH AT THE 34TH EAST ANNUAL SCIENTIFIC ASSEMBLY. During acute trauma scenarios, medical personnel are in a battle with time as the challenge becomes: is there enough time to stop ongoing blood loss? Hemorrhage from major trauma is the leading
Renowned lung injury Research Scientist Andriy Batchinsky, MD has been named The Geneva Foundation’s (Geneva) 2019 Researcher of the Year in recognition of his long-standing career pursuing ground-breaking treatments for the management of acute respiratory distress syndrome (ARDS), with notable contributions in research quality and research mentorship. Dr. Batchinsky is a principal investigator for Geneva and manager
ON-DEMAND BLOOD WILL ENABLE MILITARY MEDICAL PROFESSIONALS THE ACCESS TO QUALITY BLOOD SUPPLIES FROM ANYWHERE IN THE WORLD. The Geneva Foundation (Geneva) announces today the expansion of the 4-Defense Biotechnology, Biomanufacturing and Bioprinting Center (4D Bio3) program, a federally-funded partnership based at the Uniformed Services University (USU) and administered by Geneva, with the addition
HOUSTON, Texas, September 23, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense (DOD) to build capability at military treatment facilities in order to support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed. The CRO
The 3D BioFabrication Facility (BFF) was launched in mid-2019 and marks the first-ever 3D printer capable of manufacturing human tissue (including, someday, organs) in microgravity. The Geneva Foundation (Geneva), in partnership with the Uniformed Services University of the Health Sciences (USU), commercial space company TechShot, Inc, and 3D printer manufacturer nScrypt, Inc., have successfully
Bethesda, MD – 1 April 2020 – The Geneva Foundation (Geneva), in partnership with the Broussard Foundation, brought together more than 50 military leaders, clinicians, scientists, and experts within the physical therapy, orthopedics, physical medicine, and pain management fields for the first-ever Tri-Service Post-Operative Rehabilitation Protocol Consensus Meeting to standardize disparate protocols for military healthcare.
infectious Diseases is one of Geneva’s top research areas in terms of funding and number of programs. Geneva’s infectious disease experts are at the forefront of many therapeutic indications that protect warfighter health and global health including the lethal Sudan virus, one of six known species within the genus Ebolavirus, which poses a significant health threat across the globe.
Geneva and Jonas Philanthropies partnered in 2016 to create a joint scholarship that funds doctoral candidates seeking to improve healthcare for veterans and military personnel. Geneva and Jonas are committed to supporting nursing leaders who are spearheading critical research for the greatest healthcare issues facing our military. Click here to view the 2019 Geneva-Jonas Interim Report and read key